STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Clinical trials for STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD) explained in plain language.
Never miss a new study
Get alerted when new STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD) trials appear
Sign up with your email to follow new studies for STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Desperate patients get early access to promising drug for multiple Life-Threatening conditions
Disease control AVAILABLEThis program offers early access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like myelofibrosis, severe COVID-19, and graft-versus-host disease who have no other treatment options. It is for people who cannot join a clinical trial and…
Matched conditions: STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Experimental stem cell treatment offers hope for transplant complication
Disease control Recruiting nowThis study tests a new treatment made from stem cells (iMSC) for people with a serious complication of bone marrow transplant called graft-versus-host disease that does not respond to steroids. The goal is to see if it is safe and can help control the disease. About 12 participan…
Matched conditions: STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR AGVHD)
Phase: NA • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated May 19, 2026 12:01 UTC